



**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31 DECEMBER 2019**

**CHARITY NO: 1148335**

**PHARMACY RESEARCH UK**  
**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2019**

## **CONTENTS**

	<b>Page</b>
<b>Reference and Administrative Information</b>	<b>3</b>
<b>Foreword from the Chair</b>	<b>4</b>
<b>Trustees' Report</b>	<b>5</b>
<b>Independent Auditor's Report</b>	<b>12</b>
<b>Statement of Financial Activities</b>	<b>14</b>
<b>Balance Sheet</b>	<b>15</b>
<b>Notes to the Financial Statements</b>	<b>16</b>

**PHARMACY RESEARCH UK**  
**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2019**

REFERENCE AND ADMINISTRATIVE INFORMATION

**Registered Charity Number**

1148335

**Governing Instrument**

Pharmacy Research UK is governed by its Charitable Trust Deed dated 5 July 2012

**Principal Address**

66-68 East Smithfield, London, E1W 1AW

**Trustees**

Mr Raymond Anderson (from January 2019)

Mrs Sue Ashelby

Mr Martin Astbury

Mr Anthony Clinch (until May 2019)

Mr Peter Curphey

Professor Brian Edwards

Mr Malcolm Harrison

Ms Victoria King (from January 2019)

Professor Anthony Smith (Chair)

Mr Dimitri Varsamis (from January 2019)

**Chief Executive**

Mr Guy Parckar

**Research Manager**

Mr Ardeshier Mofidi

**Independent Auditor**

Knox Cropper LLP, 65 Leadenhall Street, London, EC3A 2AD

**Solicitors**

Boyes Turner LLP, Abbots House, Abbey Street, Reading RG1 3BD

**Investment Manager**

Investec Wealth & Investment Ltd, 30 Gresham Street, London EC2V 7QN

**Bankers**

Clydesdale Bank PLC, 91 Gresham Street, London EC2V 7BL

## PHARMACY RESEARCH UK

### FOREWORD FROM THE CHAIR

#### FOR THE YEAR ENDED 31 DECEMBER 2019

2019 was a hugely positive year for Pharmacy Research UK (PRUK) as we continued to support some fantastic research projects, while also establishing a number of excellent partnerships that will help extend our reach and impact in coming years.

It was also a strong year financially, building up our reserves to ensure that we were as well set as possible for the challenges of 2020.

We were delighted to award our first partnership grant with the College of Mental Health Pharmacy (CMHP), a partnership that we are set to continue into 2020 alongside our ongoing relationship with the British Oncology Pharmacy Association (BOPA).

We also launched our major new partnership with Diabetes UK, which has the potential to be one of the largest awards we have ever offered. The programme offers funding jointly with Diabetes UK (through their project grant scheme) for exploring how pharmacy can support patients with diabetes.

Alongside all of this we continued to offer our developmental awards and bursaries, supported by the Leverhulme Trust, helping to build the pharmacy research workforce of the future.

This report highlights our activity in 2019, showing how we continue to support important transformative pharmacy research work and support pharmacists to build their research careers. We are indebted as always to our partners, our supporters and all those who give their time to help our work such as our trustees and Scientific Advisory Panel.

PRUK faces the new challenges of 2020 from a position of strength, thanks to all the work from our team, our partners and of course the incredible pharmacy researchers whose work can make such a crucial difference in challenging times for healthcare.

#### **Note on 2020 and COVID-19**

The strong financial performance in 2019 set the charity up well for the extraordinary situation of the global pandemic in 2020. We are fortunate to have a very solid financial footing, as well as an agreed long-term strategy. Nonetheless, like most charities we have had to face some significant challenges in 2020 due to the pandemic. We remain confident of continuing to deliver to our strategy, but the impact of the pandemic for us has included:

- A significant fall in the value of our investments during the height of the lockdown, which while it has recovered significantly since remains below the levels from the start of the year;
- Delays to a number of our research projects where investigators have been furloughed, or elements of the research have had to be postponed;
- An extension to our funding calls to give extra time for applicants to respond;
- A switch to all staff working from home.

Overall, however, we remain confident in being able to continue to deliver to our strategy and to help increase pharmacy research capacity and support important new pharmacy research projects.



**Professor Anthony Smith, Chair of Trustees**

# PHARMACY RESEARCH UK

## TRUSTEES' REPORT

### FOR THE YEAR ENDED 31 DECEMBER 2019

#### OBJECTS

The object of Pharmacy Research UK, as set out in its Charitable Trust Deed, is: "To advance the education of the public in general (and particularly amongst scientists) on the subject of pharmacy and to promote research for the public benefit in all aspects of that subject and to publish the useful results."

#### VISION AND PURPOSE

Our vision of improving the health of the public through excellence in pharmacy research is a long-term challenge. The following purpose statements outline how we address this challenge:

- To promote research into the practice of pharmacy (particularly in the UK) and to publish the useful results of such research to:
  - Support the production of timely evidence that informs policy and practice relating to pharmacy's contribution to the health of the public, medicines and their use.
  - Publish and disseminate results to ensure knowledge is translated into benefit for patients, the public and the profession of pharmacy.
- To promote the health of the public by educating pharmacists (particularly in the UK) in order to enhance the standard of healthcare available to the public to:
  - Build pharmacy practice research capacity and capability through training bursaries, postgraduate research funding, fellowships and grants.
  - Develop a new generation of academic and clinical experts who can lead the debate and inform thinking, particularly within pharmacy.
- To advance and promote knowledge and skill in relation to the practice of pharmacy (particularly in the UK) for the public good to:
  - Provide a forum in which the research implications can be considered in the widest possible policy context.
  - Engage stakeholders, stimulate debate and spread knowledge about medicines and their use to the wider healthcare community and the public.

#### STRUCTURE, GOVERNANCE AND MANAGEMENT

Pharmacy Research UK is the principal research charity supporting pharmacists and pharmacy to improve healthcare for the benefit of patients and the public. Our broad ambition is to improve the health of the public through supporting and promoting excellence in pharmacy research.

Pharmacy Research UK is a charitable trust established in 2012 and is registered under the Charities Act 2011 (registration number 1148335). Pharmacy Research UK's registered office is 66-68 East Smithfield Street, London, E1W 1AW. Pharmacy Research UK is governed by its Charitable Trust Deed of 5th July 2012.

Our Trustees bring with them a wealth of skills and experience relevant for the work of the charity, including pharmacy and the pharmaceutical sciences, medicine, education, finance, health services, research, business and policy.

# PHARMACY RESEARCH UK

## TRUSTEES' REPORT

### FOR THE YEAR ENDED 31 DECEMBER 2019

We consider each of the Trustees to be independent in character and judgments and that there are no relationships or circumstances which are likely to affect, or could appear to affect, the Trustees' judgment.

Apart from where specified in our trust deed, trustees are appointed for an initial term of up to three years by a resolution of the trustees passed at a special meeting. In selecting individuals for appointment as trustees, the trustees must have regard to the skills, knowledge and experience needed for the effective administration of the charity (either the pursuit of its objects or management of the charity).

A Trustee cannot resign unless there are enough trustees remaining in office when the notice of resignation takes effect to form a quorum for meetings (a third of trustees or two trustees, whichever is the greater).

The Board of Trustees sets strategy, decides priorities, establishes funding policies and allocates budgets. The Board of Trustees draws on the advice of the Scientific Advisory Panel in relation to grant making, project management and oversight. Pharmacy Research UK supports high quality pharmacy research across a range of disciplines (social and clinical). Grant making is done through a UK wide competitive process and supported by external expert peer review and overseen by our Scientific Advisory Panel. In the reporting year, Pharmacy Research UK has continued to follow the governance processes established by the AMRC to assure the quality and rigour of our grant review and award processes.

PRUK offers a comprehensive induction programme for all new Trustees, which includes materials relating to our charitable purposes and finances, the powers of the Trustees and information about day-to-day running of Pharmacy Research UK.

#### OBJECTIVES FOR THE REPORTING YEAR

In 2018 we agreed a new strategy setting out our direction for 2019 and beyond. This set out that we are here to help pharmacy and pharmacists improve the public's health and deliver better outcomes for patients. For 2019 we set the following objectives:

- Building the pharmacy research workforce by supporting the development of research skills among pharmacists:
  - Running an award round of bursaries and developmental grants
  - Continuing to support early career pharmacy researchers through our mentoring scheme;
- Supporting high quality research into the practice of pharmacy and the provision of pharmaceutical care that can develop policy and improvements in practice:
  - Using our research strategy to focus our research into key policy areas to deliver the maximum possible impact
  - Working with our Scientific Advisory Panel (SAP) and trustee board to ensure that all of our research is delivered in line with best practice, including by maintaining our membership of the Association of Medical Research Charities (AMRC)
- Entering partnerships to amplify the value and reach of pharmacy research:
  - Run joint funding rounds with our partner organisations the British Oncology Pharmacy Association (BOPA) and the College of Mental Health Pharmacy (CMHP)
  - Develop new, targeted partnerships in line with our research priorities to help maximise our resources and deliver significant, impactful research

## PHARMACY RESEARCH UK

### TRUSTEES' REPORT

#### FOR THE YEAR ENDED 31 DECEMBER 2019

- Using and promoting research to highlight the important role of pharmacy and pharmacists in health provision:
  - Support our grantees to achieve publications and promote their research, including through journals, through the AMRC's Open Research platform, and through our own website and media channels
  - Work with others in the sector to highlight the crucial role of pharmacists in health provision, and the crucial role of research within pharmacy, including through events, social and other media.

Here's what we have been doing in 2019 to meet those goals.

- **Building the pharmacy research workforce by supporting the development of research skills among pharmacists:**

In January we launched our annual developmental awards round, offering awards and bursaries primarily to early career researchers. We funded 8 new research projects through 2019, extending the portfolio of active PRUK-funded projects to 31. In total this meant adding £110,000 of new awards in 2019. New projects covered issues as varied as pharmacists' role in pain management and designing tools to improve collaborative working between community pharmacists and GPs.

We also continue to support the Health Services Research and Pharmacy Practice (HSRPP) conference, which creates an important opportunity for early-career pharmacy researchers to network, present and discuss their work. In 2019 the conference was hosted very successfully by the team at the University of Birmingham. PRUK supports the delivery of the conference and operates as the secretariat for the organising committee. Describing the 2019 conference, the chair for the 2019 organising committee, Dr Anthony Cox, said: "The HSRPP is one of the key events in the Pharmacy Practice research calendar and 2019's was a great success. The quality of research, the thoughts it provokes, and the sense of community it fosters are so important. As chair, I was struck by how much younger researchers got from the event, which provides a friendly inclusive environment to share ideas."

- **Supporting high quality research into the practice of pharmacy and the provision of pharmaceutical care that can develop policy and improvements in practice:**

To ensure that we continue to support high quality research projects we maintain our membership of the Association of Medical Research Charities (AMRC), and ensure we follow best practice in making all of our awards. In this we are indebted to the expertise of our Scientific Advisory Panel (SAP) as well as the expert peer reviewers who support our grant-making process.

In 2019 we held a review of our decision-making processes to ensure we are making the very best use of the scientific and research expertise at our disposal. In discussion with our SAP, and our trustee board, we agreed a number of tweaks to improve and develop our awards processes, which will be fully implemented for 2020.

We also make use of tools such as Researchfish to track the impact of work that we have funded. Across the portfolio of research that we have supported in 2019 we saw more than 20 outputs from our research. The vast majority of publications were submitted as original journal articles accepted across a range of journals, from the British Journal of General Practice, to the International Journal of Pharmacy Practice.

- **Entering partnerships to amplify the value and reach of pharmacy research:**

## PHARMACY RESEARCH UK

### TRUSTEES' REPORT

#### FOR THE YEAR ENDED 31 DECEMBER 2019

In 2019 we were delighted to continue our long-standing partnership with the British Oncology Pharmacy Association (BOPA), and to award our first partnership grant with the College of Mental Health Pharmacy (CMHP). These two awards run alongside our development awards and bursaries in January and as match-funded awards they help us both to extend our reach and impact, and to deliver targeted research in key strategic areas.

Towards the end of 2019 we were also very excited to launch a new partnership with Diabetes UK, putting out a call for research exploring pharmacy and diabetes. This call is being run through Diabetes UK's project grant round, supported by PRUK, and when awarded has the potential to be one of the largest awards PRUK has ever made.

Through continuing to develop this partnership approach we are aiming to bring more funding into pharmacy research, as well as to pick up on key strategic themes. Diabetes, from diagnosis to ongoing care and management, was identified as a particular area of importance for many pharmacists when we developed our strategy, and so we are delighted to have been able to create a partnership to target important new research in this area. The COVID-19 pandemic in 2020 has impacted significantly on timelines for a number of our awards, including this partnership (the call for which was extended, along with all of Diabetes UK's open calls), but we remain very excited to be able to support work in this area.

We are also developing a number of other exciting partnerships that we expect to launch in 2020 and beyond, extending our impact, drawing more resources in pharmacy research and supporting more researchers.

- **Using and promoting research to highlight the important role of pharmacy and pharmacists in health provision:**

As well as supporting researchers to promote their research, and monitoring the reach of projects through Researchfish, we are also active users of the AMRC's OpenResearch platform, which provides an important opportunity particularly for early-career researchers to publish their research.

We maintain a presence at important sector events such as the HSRPP conference and the Royal Pharmaceutical Society (RPS) research conference, helping both to promote the role of research within pharmacy practice, and the importance of pharmacy in health provision more widely.

We also use our partnerships to help promote the importance of pharmacy, including maintaining our long-standing links with the Royal Pharmaceutical Society (RPS) and supporting them in their championing of the profession.

#### PLANS FOR THE FUTURE

##### Note on COVID-19 pandemic

As for most charities the COVID-19 pandemic means that there will be some new and different challenges for PRUK in 2020. We are very fortunate that we are in a solid financial position and so are able broadly to continue to deliver to our strategy without needing to make major changes to our plans, but there will inevitably be some impact in our approach for 2020. In particular:

- Recognising the impact of COVID-19 on many pharmacists, extending funding calls and allowing more time for the delivery of research projects;
- Even closer monitoring and management of our finances – we have set up some new protocols to ensure that we are able to respond quickly to major financial changes caused by the pandemic and lockdowns;

## PHARMACY RESEARCH UK

### TRUSTEES' REPORT

#### FOR THE YEAR ENDED 31 DECEMBER 2019

- Changing working practices – in March 2020 we moved the whole team to home-based working, and expect this to continue into 2021. We were well set up to manage this process, but continue to monitor our working practices to ensure that we are supporting our small but excellent team.

We are though still expecting to deliver strongly in line with our strategy, and our objectives for the year include:

- Building the pharmacy research workforce by supporting the development of research skills among pharmacists:
  - Delivering our developmental awards and bursaries funding call;
  - Support the delivery of the HSRPP conference hosted by Cardiff University;
  - Develop and pilot a new small 'impact awards' fund to offer low-level grants that might fall outside of our usual funding calls, but can help increase the impact of research.
- Supporting high quality research into the practice of pharmacy and the provision of pharmaceutical care that can develop policy and improvements in practice:
  - Using our research strategy to focus our research into key policy areas to deliver the maximum possible impact
  - Working with our Scientific Advisory Panel (SAP) and trustee board to ensure that all of our research is delivered in line with best practice, including by maintaining our membership of the Association of Medical Research Charities (AMRC)
- Entering partnerships to amplify the value and reach of pharmacy research:
  - Run joint funding rounds with our established partner organisations the British Oncology Pharmacy Association (BOPA) and the College of Mental Health Pharmacy (CMHP)
  - Develop new, targeted partnerships in line with our research priorities to help maximise our resources and deliver significant, impactful research
- Using and promoting research to highlight the important role of pharmacy and pharmacists in health provision:
  - Support our grantees to achieve publications and promote their research, including through journals, through the AMRC's Open Research platform, and through our own website and media channels
  - Work with others in the sector to highlight the crucial role of pharmacists in health provision, and the crucial role of research within pharmacy, including through events, social and other media.

#### **FINANCIAL REVIEW**

Full details of income and expenditure for the year are shown in the Statement of Financial Activities set out on page 14.

#### **PUBLIC BENEFIT**

The trustees have referred to the Charity Commission's guidance on public benefit when reviewing their aims and objectives and planning their future activities.

## PHARMACY RESEARCH UK

### TRUSTEES' REPORT

#### FOR THE YEAR ENDED 31 DECEMBER 2019

##### RESERVES POLICY

Total funds at the year-end were £3,468,355 (2018 £3,223,592) including endowment and restricted funds as set out on page 15.

Free reserves or unrestricted funds amounted to £3,027,903 (2018 £2,759,288). The unrestricted funds are mainly represented by a share of the investment portfolio which is held for the longer term to provide income to the charity out of which it pays for research and other project work.

##### INVESTMENT POLICY

The charity has power to invest in such assets as it sees fit. The Trustees have appointed Investec as investment managers to manage the charity's investment assets, with a brief to adopt a medium risk investment strategy whilst providing revenue for the charity's current needs while enhancing income and capital growth over the long term.

The trustees have adopted an ethical investment and fundraising policy and in particular this makes clear that the trustees do not believe it would be appropriate for Pharmacy Research UK to receive income from the tobacco industry.

##### GOING CONCERN

The Board of Trustees is of the opinion that the charity has adequate resources to continue in operational existence for the foreseeable future and there are no material uncertainties regarding the Trust's ability to do so.

##### KEY MANAGEMENT PERSONNEL

The Trustees consider the board of trustees and the senior management team to comprise the key management personnel of the charity in charge of directing and controlling, running and operating the Charity on a day to day basis.

Details of trustees' expenses are disclosed in note 5 to the financial statements.

##### RISK MANAGEMENT

The Trustees have assessed the major risks to which the charity is exposed, in particular those risks related to the operations and finances of the charity, and are satisfied that systems are in place to mitigate exposure to the major risks, although it is recognized that systems can only provide reasonable, and not absolute, assurance. These systems are reviewed at least once every year. The Trustees' have identified the following risks:

###### Risk identified

Investments will drop in value

Donations made will not be spent how the Trustees would like

###### Action taken to mitigate the risk

Trustees have appointed investment advisors to manage the investments

Trustees actively review donations and ask for updates and reports

# PHARMACY RESEARCH UK

## TRUSTEES' REPORT

### FOR THE YEAR ENDED 31 DECEMBER 2019

#### TRUSTEES' RESPONSIBILITIES STATEMENT

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). The law applicable to charities in England and Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the charity and of the incoming resources and application of resources of the charity for that period.

In preparing these statements the Trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue to operate.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Trustees and signed on behalf of the Trustees by:



Dated: 22<sup>nd</sup> October 2020

# PHARMACY RESEARCH UK

## TRUSTEES' REPORT

### FOR THE YEAR ENDED 31 DECEMBER 2019

#### **Independent auditor's report to the trustees of Pharmacy Research UK**

##### **Opinion**

We have audited the financial statements of Pharmacy Research UK (the 'charity') for the year ended 31 December 2019 which comprise the statement of financial activities, the balance sheet and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2019 and of its incoming resources and application of resources for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the Charities Act 2011.

##### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

##### **Conclusions relating to going concern**

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charity's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

##### **Other information**

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## **dependent auditor's report to the trustees of Pharmacy Research UK**

### **Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

### **Responsibilities of trustees**

As explained more fully in the trustees' responsibilities statement set out on page 11, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

### **Auditor's responsibilities for the audit of the financial statements**


We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our auditor's report.

### **Use of our report**

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken, so that we might state to the charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report or for the opinions we have formed.



28 October 2020

Knox Cropper LLP  
Statutory Auditor  
65 Leadenhall Street  
London  
EC3A 2AD

Knox Cropper is eligible for appointment as auditor of the charity by virtue of its eligibility for appointment as auditor of a company under section 1212 of the Companies Act 2006.

**PHARMACY RESEARCH UK**  
**STATEMENT OF FINANCIAL ACTIVITIES**  
**FOR THE YEAR ENDED 31 DECEMBER 2019**

	<b>Note</b>	<b>Unrestric ted Funds</b>	<b>Restricted Funds</b>	<b>Endowme nt Funds</b>	<b>Total 2019</b>	<b>Total 2018</b>
		£	£	£	£	£
<b>Income from:</b>						
<b>Investments</b>	<b>2</b>	104,264	10,262		114,526	111,710
<b>Charitable Activities</b>			90,315		90,315	151,327
<b>Other income</b>						1,193
<b>Total Income</b>		104,264	100,577		204,841	264,230
<b>Expenditure on:</b>						
<b>Raising funds</b>	<b>3</b>	21,813	2,157		23,970	24,196
<b>Charitable activities</b>	<b>3</b>	130,303	151,118		281,421	382,800
<b>Total Expenditure</b>		152,116	153,275		305,391	406,996

**PHARMACY RESEARCH UK**

**BALANCE SHEET**

**AS AT 31 DECEMBER 2019**

	<b>Note £</b>	<b>2019 £</b>	<b>2018 £</b>
<b>Fixed assets</b>			
<b>Investments</b>	7	3,573,662	3,255,223
<b>CURRENT ASSETS</b>			
<b>Debtors</b>	8	5,913	13,421
<b>Cash at Bank</b>		75,984	204,203
		81,897	217,624
<b>CURRENT LIABILITIES</b> <b>Creditors: amounts falling due within one year</b>	9	151,086	202,934
<b>NET CURRENT ASSETS</b> <b>/(LIABILITIES)</b>		(69,189)	14,690
<b>TOTAL ASSETS LESS</b> <b>CURRENT LIABILITIES</b>		3,504,473	3,269,913
<b>Creditors : amounts falling due after more than one year</b>	10	(36,118)	(46,321)
<b>NET ASSETS</b>		3,468,355	3,223,592
<b>REPRESENTED BY</b>			
<b>Endowment funds</b>		251,370	215,921
<b>Restricted funds</b>		189,082	248,383
<b>Unrestricted funds</b>		3,027,903	2,759,288
<b>TOTAL FUNDS</b>	11	3,468,355	3,223,592

Approved by the Trustees and signed on behalf of the Trustees by:



Dated: 22<sup>nd</sup> October 2020

# PHARMACY RESEARCH UK

## NOTES TO THE FINANCIAL STATEMENTS

### FOR THE YEAR ENDED 31 DECEMBER 2019

#### 1. Accounting Policies

##### 1.1 Basis of preparation of Financial statements

The financial statements are prepared under the historical cost convention with the exception of investments which are included at market value. The financial statements have been prepared in accordance with the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (Charities SORP (FRS 102 second edition – effective 1 January 2019)) and applicable UK accounting standards.

Pharmacy Research UK meets the definition of a public benefit entity under FRS 102.

##### 1.2 Going concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these financial statements.

Taking into account the impact of the Covid-19 pandemic, the trustees of the charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as a going concern. The trustees are of the opinion that the charity will have sufficient resources to meet its liabilities as they fall due.

##### 1.3 Incoming recognition

All incoming resources are included in the Statement of Financial Activities when the charity has entitlement to the funds, certainty of receipt and the amount can be measured with sufficient reliability.

Costs borne by the Royal Pharmaceutical Society on behalf of Pharmacy Research UK are reflected as income, classified as donations and as expenditure in the appropriate categories where the gift in kind to the charity can be appropriately valued.

Grants have been accounted for when receivable by the charity

##### 1.4 Expenditure recognition

Grants payable to further charitable objectives are outflows of resources in respect of grants for training and research.

Research costs relate to the charity's costs associated with pharmacy research plus an allocation of support costs.

Governance costs are costs associated with constitutional and statutory requirements, eg the costs of trustee meetings and in connection with the statutory accounts. These and other support costs are allocated across the charitable activities

##### 1.5 Investments

Investments are a form of basic financial instrument and are shown in the financial statements at market value. Movements in the market values of investments are shown as investment gains and losses in the Statement of Financial Activities.

## PHARMACY RESEARCH UK

### NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

#### FOR THE YEAR ENDED 31 DECEMBER 2019

##### 1.6 Funds

Unrestricted funds represent unrestricted income which is expendable at the discretion of the Trustees in furtherance of the objects of the Charity.

Restricted funds are subject to specific conditions imposed by the donor or by the specific terms of a trust deed or other legal measures.

Expendable endowment funds represent assets which have the restriction that the revenue generated by holding the asset is available to spend but the capital itself cannot be spent. Income generated from endowment funds is applied to restricted funds as appropriate.

##### 1.7 Estimates and judgements

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Although these estimates are based on the trustee's best knowledge of the amount, events or actions, actual results may ultimately differ from these estimates. The Trustees do not consider there to be any material estimates and judgements.

##### 1.8 Financial instruments

The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments, including debtors and creditors, are initially recognized at transaction value and subsequently measured at their settlement value.

#### 1. INVESTMENT INCOME

	Unrestricted Funds £	Restricted Funds	Endowment Funds £	Total 2019 £	Total 2019 £
<b>Income from listed</b>					
<b>Investments</b>	103,759	10,262	-	114,021	111,169
<b>Interest receivable</b>	505	-	-	505	541
	104,264	10,262	-	114,526	111,710

**PHARMACY RESEARCH UK**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

**FOR THE YEAR ENDED 31 DECEMBER 2019**

**2. EXPENDITURE**

	Direct Costs £	Grants £	Support Costs £	Total 2019 £	Total 2018 £
<b>Raising funds</b>					
<b>Investment managers</b>	23,970	-	-	23,970	24,196
<b>Charitable activities</b>					
<b>Research Funding</b>					
<b>Staff costs</b>	60,072	-	47,586	107,658	108,759
<b>Other costs</b>	8,201	153,613	11,589	173,763	274,041
	68,273	153,613	59,535	281,421	382,800
	92,243	153,613	59,535	305,391	406,996

**3. SUPPORT COSTS**

	Total 2019 £	Total 2018 £
<b>Staff costs</b>	47,586	53,831
<b>Consultants</b>	-	19,500
<b>Governance (note 6)</b>	10,820	35,457
<b>Other support costs</b>	1,129	36,304
	59,535	108,759

**5.**

	Total 2019 £	Total 2018 £
<b>The staff costs are analysed as follows:</b>		
<b>Wages and salaries</b>	94,843	99,551
<b>Social security</b>	9,544	6,903
<b>Pension costs</b>	3,271	2,303
	107,658	108,759

No employee earned total emoluments in excess of £60,000 per annum during the year under review.

## PHARMACY RESEARCH UK

### NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

#### FOR THE YEAR ENDED 31 DECEMBER 2019

#### 5.

	2019 Number	2018 Number
<b>Number of employees</b>	3	3

The charity's key management personnel comprise the chief executive and the trustees who were unpaid. The costs of key management personnel for the year was £45,821 (2018: £24,373).

The Trustees did not receive any remuneration during the year, however 5 trustees were reimbursed expenses amounting to £1,708 (2018: 6 Trustees were reimbursed £2,025) covering the costs of travel during the year.

#### 6. GOVERNANCE COSTS

	Total 2019 £	Total 2018 £
<b>Trustee expenses</b>	1,708	2,025
<b>Legal &amp; Professional fees</b>	892	24,340
<b>Bank charges</b>	120	120
<b>Auditors remuneration</b>		
<b>Current year</b>	7,020	6,798
<b>Prior year</b>	-	1,100
<b>Other services</b>	1,080	1,074
	10,820	35,457

#### 7. INVESTMENTS

	Total 2019 £	Total 2018 £
<b>Trustee expenses</b>	1,708	2,025
<b>Legal &amp; Professional fees</b>	892	24,340
<b>Bank charges</b>	120	120
<b>Auditors remuneration</b>		
<b>Current year</b>	7,020	6,798
<b>Prior year</b>	-	1,100
<b>Other services</b>	1,080	1,074
	10,820	35,457

Investments mainly comprise listed investments on international stock exchanges at market value within an investment portfolio managed by Investec Wealth & Investment.

Following the fall in world stock markets in March 2020 as a result of the Covid-19 pandemic, the value of the charity's investment portfolio as at 30 June 2020 was £3,243,503.

**PHARMACY RESEARCH UK**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

**FOR THE YEAR ENDED 31 DECEMBER 2019**

**8. DEBTORS**

	Total 2019 £	Total 2018 £
Prepayments and accrued income	5,913	13,421

**9. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	Total 2019 £	Total 2018 £
Accruals and deferred income	20,798	19,823
Grant commitments	130,288	183,111
	151,086	202,934

**10. GRANT COMMITMENTS**

	Total 2019 £	Total 2018 £
Grants falling due in less than one year	130,288	183,111
Grants falling due in more than one year	36,118	46,321
	166,406	229,432

**11. STATEMENT OF FUNDS**

Endowment	Balance at 1 <sup>st</sup> January 2019 £	Income £	Expenditure £	Investment Gains/Losses & Transfers	Balance at 31 <sup>st</sup> December 2019
Galen Trust	215,921	-	-	35,449	251,370
Restricted funds					
Leverhulme Bursary	(25,377)	47,192	(69,088)	47,273	-
Galen Trust	179,144	10,262	(27,604)	(6,603)	155,199
Leverhulme Award	71,529	25,733	(25,733)	(47,273)	24,256
HSRPP	28,087	248	(1,020)	-	27,315
BOPA	(5,000)	7,497	(9,994)	-	(7,497)
CMHP	-			-	(10,191)
	248,383	100,577	(153,275)	(6,603)	189,082
General Fund	2,759,288	104,264	(152,116)	316,467	3,027,903
	3,223,592	204,841	(305,391)	345,313	3,468,355

## PHARMACY RESEARCH UK

### NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

#### FOR THE YEAR ENDED 31 DECEMBER 2019

#### 11. STATEMENT OF FUNDS (continued)

##### **Leverhulme Bursary**

Bursaries are made annually to develop individual community pharmacists' skills and careers in research.

##### **Galen Trust**

Awards are made annually to individual pharmacist researchers. This is funded by the Galen Endowment through the Galen Trust.

##### **Leverhulme Award**

Awards are made annually for research that is of benefit to community pharmacy.

##### **Health Services Research & Pharmacy Practice (HSRPP)**

An annual conference to support novice pharmacist researchers and showcase pharmacy research.

##### **BOPA**

A collaborative project with the British Oncology Pharmacy Association (BOPA) – A registered charity promoting excellence in the pharmaceutical care of patients with cancer through education, communication and research

##### **CMHP**

A partnership with the College of Mental Health Pharmacy, a charity which aims to benefit individual care through advancing education and research in the practice of mental health pharmacy.

Prior year movements in funds

**PHARMACY RESEARCH UK**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

**FOR THE YEAR ENDED 31 DECEMBER 2019**

**12. ANALYSIS OF NET ASSETS BETWEEN FUNDS**

Current year

Current year	Unrestricted Funds £	Restricted Funds £	Endowment Funds £	Total 2019 £
Investments	3,252,033	71,473	250,156	3,573,662
Net current assets/(liabilities)	(224,130)	153,727	1,214	(69,189)
Long term liabilities	-	(36,118)	-	(36,118)
	3,027,903	189,082	251,370	3,468,355

Prior year	Unrestricted Funds £	Restricted Funds £	Endowment Funds £	Total 2019 £
Investments	2,962,439	78,076	214,708	3,255,223
Net current assets/(liabilities)	(156,830)	170,307	1,213	14,690
Long term liabilities	(46,321)	-	-	(46,321)
	2,759,288	248,383	215,921	3,223,592

**13. TRANSACTIONS WITH RELATED PARTIES**

Pharmacy Research UK is hosted by the Royal Pharmaceutical Society which during the year provided office accommodation without charge to Pharmacy Research UK. The charity is unable to put a reliable value on the office accommodation provided for free and so this is not reflected in Pharmacy Research UK's financial statements.

There were no other related party transactions in the year (2018 : none).

**PHARMACY RESEARCH UK**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

**FOR THE YEAR ENDED 31 DECEMBER 2019**

**14. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

<b>Income from:</b>	<b>Unrestricted Funds £</b>	<b>Restricted Funds £</b>	<b>Endowment Funds £</b>	<b>Total 2018 £</b>
Investments	95,035	16,675	-	111,710
Charitable Activities	2,600	148,727	-	151,327
Other income	1,193	-	-	1,193
<b>Total Income</b>	<b>98,828</b>	<b>165,402</b>	<b>-</b>	<b>264,230</b>
<b>Expenditure on:</b>				
Raising funds	20,567	3,629	-	24,196
Charitable activities	210,267	172,533		382,800
<b>Total Expenditure</b>	<b>230,834</b>	<b>176,162</b>	<b>-</b>	<b>406,996</b>
Net (Expenditure) before gains on investments	(132,006)	(10,760)	-	(142,766)
Net Losses on Investments	(6,171)	(26,870)	(166,204)	(199,245)
<b>Net Movement in Funds</b>	<b>(138,177)</b>	<b>(37,630)</b>	<b>(166,204)</b>	<b>(342,011)</b>
Total Funds Brought Forward	2,897,465	286,013	382,125	3,565,603
<b>Total Funds Carried Forward</b>	<b>2,759,288</b>	<b>248,383</b>	<b>215,921</b>	<b>3,223,592</b>